Leveraging North-South Partnerships to Advance Cell and Gene Therapy Research Training for HIV in Uganda (C&GT-Uganda)

利用南北伙伴关系推进乌干达艾滋病毒细胞和基因治疗研究培训（C

• 批准号: 10688330
• 负责人: CISSY KITYO
• 金额: $ 3.02万
• 依托单位: JOINT CLINICAL RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688330
• 关键词: Address; Admission activity; Africa; Africa South of the Sahara; Cancer Center; Caring; Cell Therapy; Cells; Clinical Research; Clinical Trials; Collaborations; Consultations; Educational Curriculum; Educational workshop; Faculty; Focus Groups; Fred Hutchinson Cancer Research Center; Genetic Variation; Goals; HIV; HIV therapy; HIV vaccine; Health Personnel; Host resistance; Institution; Interview; Joints; Needs Assessment; Persons; Population Heterogeneity; Process; Research; Research Training; Resources; Science; Scientist; Strategic Planning; Surveys; Teacher Professional Development; Technology; Training; Training Activity; Training Programs; Translational Research; Uganda; United States National Institutes of Health; Universities; Virion; Writing; antiretroviral therapy; gene therapy; graduate student; immunoreactivity; informant; innovation; interest; low and middle-income countries; meetings; programs; prospective; recruit; research and development; success; undergraduate student; virtual

There are ≈ 38 million people living with HIV, 67% of whom are in Sub-Saharan Africa (SSA). Despite the success of antiretroviral therapy (ART), there is no approved HIV vaccine or cure. Research and development (R&D) of gene and cell therapies has made progress e.g. innovative strategies to induce host resistance, immunoreactivity against HIV or making host cells unable to produce viable virions. On-going efforts include ≈40 clinical trials but none include Africa. Given the high genetic diversity of populations in SSA and the fact that the brunt of the burden is in SSA, it is critical that SSA should be involved in ongoing R&D. In 2020, the Joint Clinical Research Center (JCRC), Fred Hutchinson Cancer Center (Fred Hutch) and Caring Cross founded the Global Gene Therapy Initiative (GGTI) to include low-and-middle income countries e.g. Uganda in ongoing HIV cell and gene therapy R&D. A preliminary assessment at JCRC showed health workforce capacity gaps in almost all stages of R&D of gene and cell therapies including translational research. This is also the case at other premier research and tertiary institutions in Uganda. To address this, JCRC has sent her scientists for training in the US, and hereby propose a D71 planning process titled Leveraging North- South Partnerships to Advance Gene and cell Therapy Research Training for HIV in Uganda (G&CT-Uganda) in collaboration with Makerere University (Mak) and Fred Hutch. The goal is to prepare a D43 application for an HIV research training program in Gene and cell Therapy at JCRC and Mak. Specific Aim 1 (develop a robust strategic plan for efficiently leveraging JCRC’s North-South partnerships to plan for a research training program in Gene and cell Therapy for HIV) will be achieved through face-to-face/virtual meetings, consultations and a workshop with leaders from collaborating institutions. Specific Aim 2 (assess the critical faculty development needs in Gene and cell Therapy for HIV research at Ugandan institutions), and Specific Aim 3 (assess the training needs of potential trainees that are interested Gene and cell Therapy for HIV research in Uganda) will be achieved through a training needs assessment i.e. desk review of current training curricular, programs, faculty and resources at collaborating institutions; ii) key informant interviews and on- line surveys among trainers, admissions officers and leaders at collaborating institutions; and iii) focus group discussion among prospective trainees i.e. undergraduate and graduate students and Mak and Mbarara University of Science and Technology. Specific Aim 4 (describe the envisioned research training program in Gene and cell Therapy for HIV and identify/develop new training modules and courses to include), and Specific Aim 5 (describe trainee recruitment approaches) will be achieved through meetings, consultations and workshops with trainers, curriculum developers and leaders at collaborating institutions. Specific Aim 6 (develop and submit a D43 application to the National Institutes of Health) will be achieved through weekly meetings, writing sessions and a 14-day writing retreat involving C&GT program faculty.

尽管存在艾滋病毒感染者，但仍有约 3800 万人感染艾滋病毒，其中 67% 生活在撒哈拉以南非洲地区 (SSA)。 尽管抗逆转录病毒疗法（ART）取得了成功，但目前还没有批准的艾滋病毒疫苗或治疗方法的研究和开发。 基因和细胞疗法的（研发）取得了进展，例如诱导宿主抵抗的创新策略， 针对艾滋病毒的免疫反应或使宿主细胞无法产生可行的病毒体包括。 约 40 项临床试验，但考虑到 SSA 人口的高度遗传多样性和事实，没有一项包括非洲。 由于 SSA 首当其冲，因此 SSA 参与持续的研发至关重要。 2020 年，SSA 应该参与持续的研发。 联合临床研究中心 (JCRC)、弗雷德·哈钦森癌症中心 (Fred Hutch) 和 Caring Cross 创立了全球基因治疗倡议（GGTI），将乌干达等中低收入国家纳入其中 JCRC 的一项初步评估显示，卫生人力正在持续进行 HIV 细胞和基因治疗研发。 基因和细胞疗法研发的几乎所有阶段（包括转化研究）都存在能力差距。 为了解决这个问题，JCRC 已向乌干达其他主要研究机构和高等教育机构发送了此类案例。 她的科学家在美国接受培训，并特此提出题为“利用北方”的 D71 规划流程 南方合作伙伴关系将在乌干达推进艾滋病毒基因和细胞治疗研究培训 (G&CT-Uganda) 与麦克雷雷大学 (Mak) 和 Fred Hutch 合作，目标是为以下项目准备 D43 申请。 JCRC 和 Mak 的基因和细胞治疗 HIV 研究培训计划 有效利用 JCRC 的南北合作伙伴关系来规划研究培训的稳健计划战略 HIV基因和细胞治疗计划）将通过面对面/虚拟会议来实现， 与合作机构领导人进行磋商并举办研讨会。 具体目标 2（评估关键问题） 乌干达机构艾滋病毒研究基因和细胞治疗方面的师资发展需求）以及具体 目标 3（评估对 HIV 基因和细胞疗法感兴趣的潜在学员的培训需求 乌干达的研究）将通过培训需求评估来实现，即对当前培训进行案头审查 合作机构的课程、项目、师资和资源；ii) 关键知情人访谈和现场采访 对合作机构的培训师、招生官员和领导进行线下调查；以及 iii) 焦点小组； 潜在受训者（即本科生和研究生）以及 Mak 和 Mbarara 之间的讨论 科学技术大学。具体目标 4（描述设想的研究培训计划） HIV 的基因和细胞疗法并确定/开发新的培训模块和课程（包括），以及 具体目标 5（描述实习生招募方法）将通过会议、磋商来实现 以及与合作机构的培训师、课程开发人员和领导者举办的研讨会。 （制定并向国立卫生研究院提交 D43 申请）将通过每周实现 C&GT 项目教师参与的会议、写作会议和为期 14 天的写作静修会。